Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) Short Interest Down 86.9% in July

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) was the recipient of a significant decrease in short interest in July. As of July 31st, there was short interest totaling 56,379 shares, a decrease of 86.9% from the July 15th total of 429,660 shares. Currently, 9.0% of the shares of the stock are short sold. Based on an average trading volume of 736,949 shares, the days-to-cover ratio is presently 0.1 days.

Insider Buying and Selling

In other Shuttle Pharmaceuticals news, major shareholder Financial Lp Hrt bought 8,266 shares of Shuttle Pharmaceuticals stock in a transaction on Thursday, July 9th. The stock was bought at an average price of $3.38 per share, with a total value of $27,939.08. Following the completion of the acquisition, the insider owned 60,540 shares in the company, valued at $204,625.20. The trade was a 15.81% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Over the last three months, insiders acquired 53,398 shares of company stock valued at $181,764 and sold 38,133 shares valued at $132,128. Company insiders own 1.31% of the company’s stock.

Institutional Investors Weigh In On Shuttle Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC acquired a new stake in shares of Shuttle Pharmaceuticals in the fourth quarter valued at approximately $26,000. Boothbay Fund Management LLC acquired a new position in shares of Shuttle Pharmaceuticals during the 4th quarter worth approximately $37,000. Ikarian Capital LLC acquired a new position in shares of Shuttle Pharmaceuticals during the 4th quarter worth approximately $124,000. Finally, Connective Capital Management LLC purchased a new stake in Shuttle Pharmaceuticals in the 3rd quarter valued at approximately $357,000. 4.58% of the stock is owned by institutional investors and hedge funds.

Shuttle Pharmaceuticals Price Performance

Shuttle Pharmaceuticals stock traded down $0.17 during trading hours on Wednesday, hitting $4.14. The stock had a trading volume of 8,785 shares, compared to its average volume of 1,025,161. The stock has a market capitalization of $2.65 million, a price-to-earnings ratio of -0.09 and a beta of 0.21. Shuttle Pharmaceuticals has a 1-year low of $2.58 and a 1-year high of $55.90. The stock’s fifty day moving average is $3.71 and its two-hundred day moving average is $7.87.

Analysts Set New Price Targets

A number of analysts recently commented on SHPH shares. Weiss Ratings raised shares of Shuttle Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Wednesday, August 5th. Wall Street Zen upgraded shares of Shuttle Pharmaceuticals to a “sell” rating in a research report on Saturday, July 4th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .